Drug Profile
Lomerizine
Alternative Names: DE-090; KB 2796; Lomerizine hydrochloride; MigsisLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nippon Organon; Pfizer
- Developer Merck & Co; MSD KK; Pfizer; Santen Pharmaceutical
- Class Antimigraines; Eye disorder therapies; Piperazines; Vasodilators
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase II Glaucoma
- Discontinued Cerebral infarction
Most Recent Events
- 03 Sep 2015 Phase-II development for Glaucoma is ongoing in Japan
- 13 May 2009 Lomerizine is still in phase II development for glaucoma in Japan
- 04 Dec 2007 Lomerizine is still in phase II development for glaucoma in Japan